|
Session 124
Poster Abstracts
ART: Novel Approaches II
Tuesday, 1-4 pm
Room: Hall A |
743
 |
Ritonavir-, Lopinavir-, and Efavirenz-containing Nanoparticles: in vitro Release of ART
Chris Destache*, T Belgum, G Elsasser, K Christensen, and A Shibata
Creighton Univ, Omaha, NE, US |
744
|
HIV-1 Inhibition with Multi-valent Gold Nanoparticles
Mary Catherine Bowman*1, E Ballard2, C Akerson2, J D'Antonio2, D Feldheim3, C Melander2, and D Margolis1
1Univ of North Carolina at Chapel Hill, US; 2North Carolina State Univ, Raleigh, US; and 3Univ of Colorado, Boulder, US |
| 745 |
Anti-retroviral Nanoformulations for HIV-1-associated Cognitive Impairments
Huanyu Dou*1, C Grotepas1, M Boska1, C Destache2, B Rabinow3, and H Gendelman1
1Univ of Nebraska Med Ctr, Omaha, US; 2Creighton Univ Scho of Pharmacy and Hlth Professions, Omaha, NE, US; and 3Baxter Hlthcare Corp, Round Lake, IL, US |
746
|
The Non-peptidic Carbohydrate-binding Pradimycin Antibiotics Inhibit HIV Infection, Viral Capture by DC-SIGN, and Viral Transmission and thus May Qualify as Potential Microbicide Candidate Drugs
J Balzarini1, K Francois1, D Huskens1, J Auwerx1, K Van Laethem1, Y Igarashi2, T Oki3, and Dominique Schols*1
1Rega Inst for Med Res, KULeuven, Belgium; 2Biotech Res Ctr, Toyama Prefectural Univ, Japan; and 3Keck Sch of Med, Univ of Southern California, Los Angeles, US |
747
|
Carbohydrate-binding Agents Inhibit HIV-1 Infection of Human Primary Monocyte-derived Macrophages and Prevent MDM-directed Viral Capture and Subsequent Transmission to CD4+ T Lymphocytes
Michela Pollicita*1, D Schols2, S Aquaro3, W Peumans4, E Van Damme4, C Perno1, and J Balzarini2
1Univ of Tor Vergata, Rome, Italy; 2Rega Inst for Med Res, KULeuven, Belgium; 3Univ of Calabria, Rende, Italy; and 4Ghent Univ, Belgium |
| 748 |
CD7-specific Single Chain Antibody-mediated Delivery of siRNA to T Cells Inhibits HIV Replication in a Humanized Mouse Model
Priti Kumar*1, H Ban2, S Kim1, M Peipp3, G Fey3, L Schultz4, N Manjunath1, S Lee2, and P Shankar1
1Immune Disease Inst, Boston, MA, US; 2Hanyang Univ, Seoul, Korea; 3Univ of Erlangen, Germany; and 4Jackson Lab, Bar Harbor, ME, US |
749
|
Protein Phosphatase-1 as a New Target for Anti-HIV-1 Therapeutics
T Ammosova1, D Kovalskyy2, V Yedavalli3, V Gordeuk1, K T Jeang3, and Sergei Nekhai*1
1Howard Univ, Washington, DC,US; 2Natl Taras Shevchenko Univ, Kiev, Ukraine; and 3NIAID, NIH, Bethesda, MD, US |
750
|
Anti-HIV Activity of Aprepitant and Synergistic Interactions with Other Antiretrovirals
Mark Manak*1, D Moshkoff1, L Nguyen1, S Dryga1, J Lathey2, and S Douglas3
1SeraCare Life Sci, Inc, Gaithersburg, MA, US; 2Sanofi Pasteur, Swiftwater, PA, US; and 3Children`s Hosp Philadelphia, PA, US |
| 751 |
A Novel Inhibitor of the HIV-1 Vpu Protein Can Inhibit the Replication of SHIV in a CD4+ T Cell Line
Sarah Hill*1, C Luscombe2, J Wilkinson2, G Ewart2, and E Stephens1
1Univ of Kansas Med Ctr, Kansas City, US and 2Biotron Ltd |
752
|
Evaluation of the Lymphocyte Trafficking Drug FTY720 in SHIV-infected Rhesus Macaques
Ellen Kersh*1, M Premenko-Lanier2, W Luo1, D Adams1, J Mitchell1, G Garcia-Lerma1, S Butera1, T Folks1, R Otten1, and J Altman2
1CDC, Atlanta, GA, US and 2Emory Vaccine Ctr, Atlanta, GA, US |
753a
|
Lentiviral Delivered VRX496 Long Antisense Sequences Exerts Molecular Pressure on HIV-1 in Human Subjects
Vladimir Lukashov*1, M Quinones-Mateu2, G McGarrity3, T Rebello3, and L Humeau3
1Academic Med Ctr, Amsterdam, The Netherlands; 2Diagnostic Hybrids Inc, Athens, OH, US; and 3VIRxSYS Corp, Gaithersburg, MD, US |
753b
|
Dose Response Curve Slope Sets Class-specific Limits on Inhibitory Potential of Anti-HIV Drugs
Lin Shen*1, S Peterson1, A Sedaghat1, M McMahon1, M Callender1, H Zhang1, Y Zhou1, K Anderson2, E Acosta3, and R Siliciano1,4
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2Yale Univ Sch of Med, New Haven, CT, US; 3Univ of Alabama at Birmingham Sch of Med, US; and 4Howard Hughes Med Inst, Baltimore, MD, US |
|
